Global Communicable Diseases Treatment Market – Industry Trends and Forecast to 2029

Market Analysis and Size                              

According to the World Health Organization (WHO), about 37.9 million people worldwide were infected with HIV in 2018. The majority of this prevalence is seen in poor and middle-income nations, with 66 percent of the population living in Sub-Saharan Africa. In 2016, around 6.3 million new cases of tuberculosis (TB) were reported, according to the WHO's 2017 Global Tuberculosis Report. As per the research, the new cases accounted for 61 percent of the anticipated 10.4 million cases of tuberculosis. Infectious agents such as fungi, viruses, bacteria, and parasites are the most common causes of communicable disorders.

Furthermore, some communicable diseases are transmitted by the air, contaminated food or beverages, contaminated surfaces, and blood or bodily fluids. A bite from an infected animal can also spread infectious disease. Some communicable diseases have relatively minor symptoms that go away on their own. Others may result in severe symptoms or life-threatening complications. Depending on the disease process and clinical appearance, patients require different treatments.

Data Bridge Market Research analyses that the communicable diseases treatment market was valued at USD 28.1 billion in 2021 and is expected to reach USD 47.0 billion by 2029, registering a CAGR of 6.64% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Définition du marché

Une maladie contagieuse est une maladie qui peut être transmise d'une personne à une autre ou d'un animal à un autre. Ces maladies sont causées par des agents pathogènes, notamment des virus, des bactéries et des champignons. Les vaccins sont un outil puissant pour prévenir les maladies virales. Des antibiotiques peuvent être nécessaires pour traiter une infection bactérienne. Ces médicaments peuvent aider à tuer les bactéries ou à les ralentir suffisamment pour que le système immunitaire puisse les combattre. Des prescriptions d'antifongiques et, dans de rares cas, des médicaments intraveineux peuvent être nécessaires en cas d'infection fongique grave ou chronique. Des pommades topiques en vente libre peuvent être utilisées pour traiter diverses maladies bénignes telles que la teigne et le pied d'athlète.

Dynamique du marché du traitement des maladies transmissibles

Conducteurs

• Augmentation de l'incidence des maladies infectieuses

L'augmentation des cas de maladies infectieuses telles que l'hépatite, la diphtérie et la maladie de Lyme constituera un facteur majeur qui accroîtra le taux de croissance du marché. Selon les Centers for Disease Control and Prevention, en 2016 et 2017, il y a eu respectivement 0,62 et 1,03 nouveaux cas de maladies transmissibles pour 100 000 personnes aux États-Unis.

• Augmenter les investissements dans les infrastructures de santé

Un autre facteur important qui influence le taux de croissance du marché du traitement des maladies transmissibles est l’augmentation des dépenses de santé, qui contribue à améliorer son infrastructure. En outre, diverses organisations gouvernementales visent à améliorer l’infrastructure des soins de santé en augmentant le financement, ce qui influencera davantage la dynamique du marché.

• Augmentation du nombre de personnes âgées

L'augmentation du nombre de personnes âgées devrait accroître le taux de croissance du marché. Selon l'estimation de World Ageing 2020, il y aura 727 millions de personnes âgées de 65 ans et plus en 2020. En 2050, cette population devrait atteindre 1,5 milliard. La proportion de la population gériatrique devrait augmenter. La population âgée devrait augmenter, ce qui renforcera le taux de croissance du marché car elle est plus exposée aux maladies transmissibles.

En outre, le nombre croissant d'initiatives gouvernementales visant à sensibiliser les gens et à réduire le mode de vie sédentaire devrait accroître le marché du traitement des maladies transmissibles. Parallèlement, l'augmentation du niveau de revenu disponible et la multiplication des initiatives gouvernementales favorables vont accroître le taux de croissance du marché.

Opportunités

• Hausse des activités de R&D 

La croissance du marché est alimentée par un nombre croissant d'activités de recherche et développement. Cela offrira des opportunités bénéfiques pour la croissance du marché du traitement des maladies transmissibles. La surconsommation d'antibiotiques conduit à la résistance microbienne. En conséquence, le marché mondial devrait être propulsé par le lancement de thérapies et de produits innovants. Les acteurs du secteur travaillent sur de nouveaux produits et investissent dans la recherche et le développement. Par exemple, Merck Sharp & Dohme Corp est l'un des principaux concurrents du marché, avec un programme de recherche et développement agressif visant à répondre aux besoins médicaux non satisfaits en matière de prévention et de traitement des maladies infectieuses.

En outre, la croissance du marché est alimentée par les investissements visant à développer des technologies de pointe et à accroître le nombre de marchés émergents. Ces facteurs offriront des opportunités bénéfiques pour la croissance du marché du traitement des maladies transmissibles.

Contraintes/Défis

D’autre part, le coût élevé associé au traitement freinera le taux de croissance du marché du traitement des maladies transmissibles au cours de la période 2022-2029. Le manque d’infrastructures de santé dans les économies en développement et l’expiration des brevets mettront à mal le marché du traitement des maladies transmissibles. En outre, le manque de sensibilisation de la population et les mauvaises politiques de remboursement limiteront et entraveront davantage le taux de croissance du marché au cours de la période de prévision 2022-2029.

This communicable diseases treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the communicable diseases treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Communicable diseases treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

COVID-19 Impact on Communicable Diseases Treatment Market

The COVID-19 pandemic had a negative influence on most companies' overall sales, but it had a favourable impact on the infectious disease diagnostics industry since infectious disease diagnostic procedures were used for COVID-19 testing. People postponed health checkups as a result of the COVID-19 epidemic, reducing the number of tests performed and reagent sales. However, as governments gradually loosen travel restrictions, testing numbers are expected to rise again. With the COVID-19 pandemic, dealing with infectious disease has become a major medical concern all around the world. Apart from vaccinations and therapeutic medications, there is a growing demand for more precise and simple testing technologies and the expansion of testing structures. As governments and healthcare providers face unprecedented problems, COVID-19 had an impact on the regulatory environment and practices. Regulatory agencies used a variety of techniques to expedite the approval of diagnostic products. Companies have made strategic decisions to implement COVID-19 rapid tests, maintain revenue, and mitigate COVID-19's impact on their operating capabilities.

Recent Development

• In December 2021, Roche announced the launch of first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. Cobas HBV, cobas HIV-1, cobas HIV-1/HIV-2 Qualitative, cobas HCV, and the cobas omni Utility Channel kit are some of them. These new products broaden Roche Molecular's range by delivering consistent performance and efficiency for low, medium, and high volume molecular laboratory testing.

Global Communicable Diseases Treatment Market Scope

The communicable diseases treatment market is segmented on the basis of indication, type, treatment type, infectious agent, mode of transmission, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Gastroenteritis
• Gonorrhoea
• Whooping Cough
• Common Cold
• HIV/AIDS
• Pink Eye
• Hepatitis
• Others

Treatment Type

• Vaccine
• Therapeutics
• Antibiotics
• Antivirals
• Antifungal
• Antiparasitics
• Others
• Others

Infectious Agent

• Bacteria
• Viruses
• Fungi/Parasites

Mode of Transmission

• Direct Contact
• Person-to-person Contact
• Droplet Spread
• Others
• Indirect Contact
• Airborne Transmission
• Contaminated Objects
• Food and Drinking Water
• Others

Type

• Sexually Transmitted Diseases
• Helminthic Diseases
• Contact Communicable Diseases
• Oral Contamination Diseases
• Air Borne Diseases

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Communicable Diseases Treatment Market Regional Analysis/Insights

The communicable diseases treatment market is analyzed and market size insights and trends are provided by country, indication, type, treatment type, infectious agent, mode of transmission, route of administration, end-users and distribution channel as referenced above.

The countries covered in the communicable diseases treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America and Europe dominate the communicable diseases treatment market because of the rising healthcare expenditure and vulnerable AIDS population in this region. Additionally, the growing focus of major key players in research and development activities will further propel the market's growth rate.

Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the growing number of patient populations and the large number of generic manufacturers in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Communicable Diseases Treatment Market Share Analysis

The communicable diseases treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to communicable diseases treatment market.

Some of the major players operating in the communicable diseases treatment market are:

• Eli Lilly and Company (U.S.)
• AstraZeneca (U.K.)
• Novartis AG (Switzerland)
• Johnson & Johnson Private Limited (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• Bausch Health Companies Inc. (Canada)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Sanofi (France)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Endo International plc (Ireland)
• Apotex Inc. (Canada)
• Amneal Pharmaceuticals LLC. (U.S.)
• Fresenius Kabi AG (Germany)
• Torrent Pharmaceuticals Ltd. (India)

SKU-53413